#United States #New York #Inc. #Early Cancer Detection #Freenome Holdings #Perceptive Capital

Strategic Partnership: Perceptive Capital Solutions and Freenome Join Forces

In a significant advancement for the healthcare industry, Perceptive Capital Solutions Corp (PCSC) and Freenome Holdings, Inc. have recently announced the effectiveness of their registration statement for a proposed business combination. This partnership, aimed at uniting PCSC's resources and Freenome's innovative cancer detection technologies, marks an essential step in their journey towards enhanced cancer diagnostics.

The Merger Details

On June 17, 2026, the U.S. Securities and Exchange Commission (SEC) declared effective the registration statement regarding the business combination, which is set to revolutionize early cancer detection with Freenome's proprietary blood-based tests. An extraordinary general meeting for PCSC shareholders is scheduled for July 9, 2026, where the details of the merger will be discussed and voted upon.

As the parties work towards closing the deal, they anticipate completion by July 2026, contingent on fulfilling certain conditions outlined in their agreement. Following the successful merger, PCSC is set to rebrand itself as "Freenome, Inc."—a strategic move that aligns the company more closely with Freenome's mission to enhance cancer screening capabilities globally.

About Freenome's Technology

Freenome is at the forefront of early cancer detection, leveraging a unique multiomics platform that combines various biological signals alongside cutting-edge artificial intelligence and machine learning. This innovative approach allows the company to capture subtle signs of cancer, significantly increasing detection rates in earlier stages of the disease when treatment is often more effective.

The company's commitment to addressing the complexities of cancer detection stems from an understanding that a singular technology cannot adequately identify the myriad forms that cancer may take. Freenome's multifaceted strategy allows them to adapt to the disease's inherent variability.

Insights from Leadership

Leaders from both organizations have conveyed enthusiasm about the impending merger. Joseph Edelman, Chairman of PCSC, emphasizes, "This merger represents a pivotal moment in our efforts to drive forward innovative cancer screening solutions. Together with Freenome's expertise, we can make impactful strides in early cancer detection."

Freenome’s executives echo this sentiment, expressing confidence that joining forces with PCSC will empower them to accelerate their product offerings and enhance market access, ultimately benefiting patients worldwide.

Moving Forward

As momentum builds towards finalizing this business combination, stakeholders, including shareholders and potential investors, are encouraged to stay informed through forthcoming communications with detailed information about the merger. The definitive proxy statement/prospectus, which outlines all necessary information regarding the proposed business combination, will be sent to shareholders starting June 12, 2026.

More importantly, readers are urged to thoroughly review the documents when available, as they will contain critical insights into the operational plans post-merger and the strategic directions the combined entity intends to pursue.

In conclusion, the impending merger between Perceptive Capital Solutions Corp and Freenome Holds the promise of reshaping the landscape of early cancer detection. By combining their strengths, the two companies are poised to bring innovative solutions to healthcare providers and patients alike, marking a substantial leap forward in fighting cancer effectively.